COvid MEdicaTion (COMET) study : protocol for a cohort study
© European Association of Hospital Pharmacists 2020. Re-use permitted under CC BY. Published by BMJ..
Various theories about drugs such as ACE inhibitors or angiotensin II receptor blockers (ARBs) in relation to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and clinical outcomes of COVID-19 are circulating in both mainstream media and medical literature. These are based on the fact that ACE2 facilitates SARS-CoV-2 cell invasion via binding of a viral spike protein to ACE2. However, the effect of ACE inhibitors, ARBs and other drugs on ACE2 is unclear and all theories are based on conflicting evidence mainly from animal studies. Therefore, clinical evidence is urgently needed. The aim of this study is to investigate the relationship between use of these drugs on clinical outcome of patients with COVID-19. Patients will be included from several hospitals in Europe. Data will be collected in a user-friendly database (Digitalis) on an external server. Analyses will be adjusted for sex, age and presence of cardiovascular disease, hypertension and diabetes. These results will enable more rational choices for randomised controlled trials for preventive and therapeutic strategies in COVID-19.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
---|---|
Enthalten in: |
European journal of hospital pharmacy : science and practice - 27(2020), 4 vom: 06. Juli, Seite 191-193 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Sablerolles, Roos S G [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 09.07.2020 Date Revised 18.12.2020 published: Print Citation Status MEDLINE |
---|
doi: |
10.1136/ejhpharm-2020-002329 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM311653642 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM311653642 | ||
003 | DE-627 | ||
005 | 20231225142719.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1136/ejhpharm-2020-002329 |2 doi | |
028 | 5 | 2 | |a pubmed24n1038.xml |
035 | |a (DE-627)NLM311653642 | ||
035 | |a (NLM)32587077 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Sablerolles, Roos S G |e verfasserin |4 aut | |
245 | 1 | 0 | |a COvid MEdicaTion (COMET) study |b protocol for a cohort study |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 09.07.2020 | ||
500 | |a Date Revised 18.12.2020 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © European Association of Hospital Pharmacists 2020. Re-use permitted under CC BY. Published by BMJ. | ||
520 | |a Various theories about drugs such as ACE inhibitors or angiotensin II receptor blockers (ARBs) in relation to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and clinical outcomes of COVID-19 are circulating in both mainstream media and medical literature. These are based on the fact that ACE2 facilitates SARS-CoV-2 cell invasion via binding of a viral spike protein to ACE2. However, the effect of ACE inhibitors, ARBs and other drugs on ACE2 is unclear and all theories are based on conflicting evidence mainly from animal studies. Therefore, clinical evidence is urgently needed. The aim of this study is to investigate the relationship between use of these drugs on clinical outcome of patients with COVID-19. Patients will be included from several hospitals in Europe. Data will be collected in a user-friendly database (Digitalis) on an external server. Analyses will be adjusted for sex, age and presence of cardiovascular disease, hypertension and diabetes. These results will enable more rational choices for randomised controlled trials for preventive and therapeutic strategies in COVID-19 | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Observational Study | |
650 | 4 | |a adverse effects | |
650 | 4 | |a clinical pharmacy | |
650 | 4 | |a hypertension | |
650 | 4 | |a vascular medicine | |
650 | 4 | |a virology | |
650 | 7 | |a Angiotensin II Type 1 Receptor Blockers |2 NLM | |
650 | 7 | |a Angiotensin-Converting Enzyme Inhibitors |2 NLM | |
650 | 7 | |a Recombinant Proteins |2 NLM | |
650 | 7 | |a Peptidyl-Dipeptidase A |2 NLM | |
650 | 7 | |a EC 3.4.15.1 |2 NLM | |
650 | 7 | |a ACE2 protein, human |2 NLM | |
650 | 7 | |a EC 3.4.17.23 |2 NLM | |
650 | 7 | |a Angiotensin-Converting Enzyme 2 |2 NLM | |
650 | 7 | |a EC 3.4.17.23 |2 NLM | |
700 | 1 | |a Hogenhuis, Freija E F |e verfasserin |4 aut | |
700 | 1 | |a Lafeber, Melvin |e verfasserin |4 aut | |
700 | 1 | |a van de Loo, Bob P A |e verfasserin |4 aut | |
700 | 1 | |a Borgsteede, Sander D |e verfasserin |4 aut | |
700 | 1 | |a Boersma, Eric |e verfasserin |4 aut | |
700 | 1 | |a Versmissen, Jorie |e verfasserin |4 aut | |
700 | 1 | |a van der Kuy, Hugo M |e verfasserin |4 aut | |
700 | 0 | |a COMET Research team |e verfasserin |4 aut | |
700 | 1 | |a Aleman, Jacomien |e investigator |4 oth | |
700 | 1 | |a Nagele, Fiona |e investigator |4 oth | |
700 | 1 | |a Stemer, Gunar |e investigator |4 oth | |
700 | 1 | |a Tournoy, Jos |e investigator |4 oth | |
700 | 1 | |a derLinden, Lorenz van |e investigator |4 oth | |
700 | 1 | |a Krusteva, Irena |e investigator |4 oth | |
700 | 1 | |a Safipour, Zohreh |e investigator |4 oth | |
700 | 1 | |a Bengaard, Anne Kathrine |e investigator |4 oth | |
700 | 1 | |a Houlind, Morten Baltzer |e investigator |4 oth | |
700 | 1 | |a Kerjean, Nathalie Pons |e investigator |4 oth | |
700 | 1 | |a Grand, Jennifer Le |e investigator |4 oth | |
700 | 1 | |a Zenico, Carito |e investigator |4 oth | |
700 | 1 | |a Berlinghini, Silvia |e investigator |4 oth | |
700 | 1 | |a Caruso, Francesca |e investigator |4 oth | |
700 | 1 | |a Peverini, Manola |e investigator |4 oth | |
700 | 1 | |a Pieraccini, Fabio |e investigator |4 oth | |
700 | 1 | |a Bini, Katia |e investigator |4 oth | |
700 | 1 | |a Candela, Marco |e investigator |4 oth | |
700 | 1 | |a DiCarlo, Marco |e investigator |4 oth | |
700 | 1 | |a Grinta, Roberto |e investigator |4 oth | |
700 | 1 | |a Salaffi, Fausto |e investigator |4 oth | |
700 | 1 | |a Schimizzi, Anna Maria |e investigator |4 oth | |
700 | 1 | |a Tardella, Marika |e investigator |4 oth | |
700 | 1 | |a Verri, Federica |e investigator |4 oth | |
700 | 1 | |a Tessari, Roberto |e investigator |4 oth | |
700 | 1 | |a Marchesini, Francesca |e investigator |4 oth | |
700 | 1 | |a Chessa, Paola |e investigator |4 oth | |
700 | 1 | |a Gambera, Marco |e investigator |4 oth | |
700 | 1 | |a Martignoni, Isabella |e investigator |4 oth | |
700 | 1 | |a Rametta, Giovanna |e investigator |4 oth | |
700 | 1 | |a Pappalardo, Francesco |e investigator |4 oth | |
700 | 1 | |a Rossi, Lucia |e investigator |4 oth | |
700 | 1 | |a Fantini, Laura |e investigator |4 oth | |
700 | 1 | |a Maria, Elisa |e investigator |4 oth | |
700 | 1 | |a Gambarelli, Giorgia |e investigator |4 oth | |
700 | 1 | |a Berlinghini, Sivlia |e investigator |4 oth | |
700 | 1 | |a Martini, Gabriella |e investigator |4 oth | |
700 | 1 | |a Pagliarino, Simone |e investigator |4 oth | |
700 | 1 | |a Loche, Elena |e investigator |4 oth | |
700 | 1 | |a Agnoletto, Laura |e investigator |4 oth | |
700 | 1 | |a Peverini, Manola |e investigator |4 oth | |
700 | 1 | |a Boni, Gloria |e investigator |4 oth | |
700 | 1 | |a Falcao, Margarida |e investigator |4 oth | |
700 | 1 | |a Farinha, Helena |e investigator |4 oth | |
700 | 1 | |a Mendes, Dina |e investigator |4 oth | |
700 | 1 | |a Rijo, Joao |e investigator |4 oth | |
700 | 1 | |a Carmo, Ines |e investigator |4 oth | |
700 | 1 | |a Falcao, Fatima |e investigator |4 oth | |
700 | 1 | |a Soares, Joana |e investigator |4 oth | |
700 | 1 | |a Solano, Mariana |e investigator |4 oth | |
700 | 1 | |a Viegas, Erica |e investigator |4 oth | |
700 | 1 | |a Miarons, Marta |e investigator |4 oth | |
700 | 1 | |a QueraltGorgas, Maria |e investigator |4 oth | |
700 | 1 | |a Yubero, Cristina García |e investigator |4 oth | |
700 | 1 | |a Horcajada, Laura Portillo |e investigator |4 oth | |
700 | 1 | |a Keijzers, Kim |e investigator |4 oth | |
700 | 1 | |a Lim, Silke |e investigator |4 oth | |
700 | 1 | |a Haelst, Ingrid van |e investigator |4 oth | |
700 | 1 | |a Andrews, Louise |e investigator |4 oth | |
700 | 1 | |a Sombogaard, Ferdi |e investigator |4 oth | |
700 | 1 | |a Berg, Roland van den |e investigator |4 oth | |
700 | 1 | |a Boutkourt, Firdaouss |e investigator |4 oth | |
700 | 1 | |a Kemper, Marleen |e investigator |4 oth | |
700 | 1 | |a Slob, Elise |e investigator |4 oth | |
700 | 1 | |a Kan, Erikvan |e investigator |4 oth | |
700 | 1 | |a Helmers, Annemiek Otten |e investigator |4 oth | |
700 | 1 | |a Filius, Margreet |e investigator |4 oth | |
700 | 1 | |a Hemminga, Wietske |e investigator |4 oth | |
700 | 1 | |a Ghazarian, Caroline |e investigator |4 oth | |
700 | 1 | |a Hilarius, Doranne |e investigator |4 oth | |
700 | 1 | |a Kappers, Mariette |e investigator |4 oth | |
700 | 1 | |a Etten, Ronald van |e investigator |4 oth | |
700 | 1 | |a Onzenoort, Hein van |e investigator |4 oth | |
700 | 1 | |a Wijngaarden, Peter van |e investigator |4 oth | |
700 | 1 | |a Diepstraten, Jeroen |e investigator |4 oth | |
700 | 1 | |a Roelofsen, Eveline |e investigator |4 oth | |
700 | 1 | |a Meuwese, Edmé Roobol |e investigator |4 oth | |
700 | 1 | |a Wierenga, Peter |e investigator |4 oth | |
700 | 1 | |a Graaf, Ingrid Hoogendoorn de |e investigator |4 oth | |
700 | 1 | |a Verdonk, Judith |e investigator |4 oth | |
700 | 1 | |a Ebbens, Marieke |e investigator |4 oth | |
700 | 1 | |a Hendriksen, Linda |e investigator |4 oth | |
700 | 1 | |a Linden, Paul van der |e investigator |4 oth | |
700 | 1 | |a Crommentuijn, Kristel |e investigator |4 oth | |
700 | 1 | |a Wit, Hugo de |e investigator |4 oth | |
700 | 1 | |a Guda, Kaylen |e investigator |4 oth | |
700 | 1 | |a Dijk, Suzanne van |e investigator |4 oth | |
700 | 1 | |a Bosch, Tessa |e investigator |4 oth | |
700 | 1 | |a Krens, Lisanne |e investigator |4 oth | |
700 | 1 | |a Slijfer, Monique |e investigator |4 oth | |
700 | 1 | |a Hurkens, Kim |e investigator |4 oth | |
700 | 1 | |a Wong, Dennis |e investigator |4 oth | |
700 | 1 | |a Deben, Debbie |e investigator |4 oth | |
700 | 1 | |a Ezinga, Marieke |e investigator |4 oth | |
700 | 1 | |a Nieuwkoop, Kees van |e investigator |4 oth | |
700 | 1 | |a Visser, Loes |e investigator |4 oth | |
700 | 1 | |a Boemaars, Ebbie |e investigator |4 oth | |
700 | 1 | |a Maat, Barbara |e investigator |4 oth | |
700 | 1 | |a Derijks, Luc |e investigator |4 oth | |
700 | 1 | |a Janssen, Paddy |e investigator |4 oth | |
773 | 0 | 8 | |i Enthalten in |t European journal of hospital pharmacy : science and practice |d 2012 |g 27(2020), 4 vom: 06. Juli, Seite 191-193 |w (DE-627)NLM225772213 |x 2047-9956 |7 nnns |
773 | 1 | 8 | |g volume:27 |g year:2020 |g number:4 |g day:06 |g month:07 |g pages:191-193 |
856 | 4 | 0 | |u http://dx.doi.org/10.1136/ejhpharm-2020-002329 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 27 |j 2020 |e 4 |b 06 |c 07 |h 191-193 |